BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu F, Huang X, Li Y, Chen Y, Lin L. m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD. Mol Ther Nucleic Acids 2021;24:780-91. [PMID: 33996259 DOI: 10.1016/j.omtn.2021.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Lu M, Zhan H, Liu B, Li D, Li W, Chen X, Zhou X. N6-methyladenosine-related non-coding RNAs are potential prognostic and immunotherapeutic responsiveness biomarkers for bladder cancer. EPMA J 2021;12:589-604. [PMID: 34950253 DOI: 10.1007/s13167-021-00259-w] [Reference Citation Analysis]
2 Wang D, Zhou Y, Hua L, Li J, Zhu N, Liu Y. CDK3, CDK5 and CDK8 Proteins as Prognostic and Potential Biomarkers in Colorectal Cancer Patients. IJGM 2022;Volume 15:2233-45. [DOI: 10.2147/ijgm.s349576] [Reference Citation Analysis]
3 Li C, Su F, Liang Z, Zhang L, Liu F, Fan W, Li Z. Macrophage M1 regulatory diabetic nephropathy is mediated by m6A methylation modification of lncRNA expression. Molecular Immunology 2022;144:16-25. [DOI: 10.1016/j.molimm.2022.02.008] [Reference Citation Analysis]
4 Fei X, Hu C, Wang X, Lu C, Chen H, Sun B, Li C. Construction of a Ferroptosis-Related Long Non-coding RNA Prognostic Signature and Competing Endogenous RNA Network in Lung Adenocarcinoma. Front Cell Dev Biol 2021;9:751490. [PMID: 34820377 DOI: 10.3389/fcell.2021.751490] [Reference Citation Analysis]
5 Zhang C, Chang L, Yao Y, Chao C, Ge Z, Fan C, Yu H, Wang B, Yang J. Role of the CBX Molecular Family in Lung Adenocarcinoma Tumorigenesis and Immune Infiltration. Front Genet 2021;12:771062. [PMID: 34966411 DOI: 10.3389/fgene.2021.771062] [Reference Citation Analysis]
6 Zhan L, Zhang J, Zhu S, Liu X, Zhang J, Wang W, Fan Y, Sun S, Wei B, Cao Y. N6-Methyladenosine RNA Modification: An Emerging Immunotherapeutic Approach to Turning Up Cold Tumors. Front Cell Dev Biol 2021;9:736298. [PMID: 34616742 DOI: 10.3389/fcell.2021.736298] [Reference Citation Analysis]
7 Ouyang W, Jiang Y, Bu S, Tang T, Huang L, Chen M, Tan Y, Ou Q, Mao L, Mai Y, Yao H, Yu Y, Lin X. A Prognostic Risk Score Based on Hypoxia-, Immunity-, and Epithelialto-Mesenchymal Transition-Related Genes for the Prognosis and Immunotherapy Response of Lung Adenocarcinoma. Front Cell Dev Biol 2022;9:758777. [DOI: 10.3389/fcell.2021.758777] [Reference Citation Analysis]
8 Li D, Liang J, Cheng C, Guo W, Li S, Song W, Song Z, Bai Y, Zhang Y, Wu X, Zhang W. Identification of m6A-Related lncRNAs Associated With Prognoses and Immune Responses in Acute Myeloid Leukemia. Front Cell Dev Biol 2021;9:770451. [PMID: 34869365 DOI: 10.3389/fcell.2021.770451] [Reference Citation Analysis]
9 Shen S, Yang D, Yang Y, Chen Y, Xiong J, Hu X, Bukhari I. A Novel Prognostic Ferroptosis-Related lncRNA Signature Associated with Immune Landscape in Invasive Breast Cancer. Disease Markers 2022;2022:1-25. [DOI: 10.1155/2022/9168556] [Reference Citation Analysis]
10 Liu XS, Zhou LM, Yuan LL, Gao Y, Kui XY, Liu XY, Pei ZJ. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis. Front Immunol 2021;12:724741. [PMID: 34335635 DOI: 10.3389/fimmu.2021.724741] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Lei L, Li N, Yuan P, Liu D. A new risk model based on a 11-m6A-related lncRNA signature for predicting prognosis and monitoring immunotherapy for gastric cancer. BMC Cancer 2022;22:365. [PMID: 35382776 DOI: 10.1186/s12885-021-09062-2] [Reference Citation Analysis]
12 Liu LP, Lu L, Zhao QQ, Kou QJ, Jiang ZZ, Gui R, Luo YW, Zhao QY. Identification and Validation of the Pyroptosis-Related Molecular Subtypes of Lung Adenocarcinoma by Bioinformatics and Machine Learning. Front Cell Dev Biol 2021;9:756340. [PMID: 34805165 DOI: 10.3389/fcell.2021.756340] [Reference Citation Analysis]
13 He Y, Zhang H, Zhang Y, Wang P, Zhu K, Ba Y. Comprehensive Characterization of Transforming Growth Factor Beta Receptor 1 in Stomach Adenocarcinoma Identifies a Prognostic Signature for Predicting Clinical Outcomes and Immune Infiltrates. IJGM 2022;Volume 15:3375-91. [DOI: 10.2147/ijgm.s353879] [Reference Citation Analysis]
14 Lu Y, Luo X, Wang Q, Chen J, Zhang X, Li Y, Chen Y, Li X, Han S. A Novel Necroptosis-Related lncRNA Signature Predicts the Prognosis of Lung Adenocarcinoma. Front Genet 2022;13:862741. [DOI: 10.3389/fgene.2022.862741] [Reference Citation Analysis]
15 Guo L, Yang H, Zhou C, Shi Y, Huang L, Zhang J. N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy. Front Immunol 2021;12:773570. [PMID: 34956201 DOI: 10.3389/fimmu.2021.773570] [Reference Citation Analysis]
16 Gao C, Kong N, Zhang F, Tang T, Li J, Ding H, Sun Z, Wu L, Xu M. Risk stratification of lung adenocarcinoma using a nomogram combined with ferroptosis-related LncRNAs and subgroup analysis with immune and N6-methyladenosine modification. BMC Med Genomics 2022;15. [DOI: 10.1186/s12920-022-01164-5] [Reference Citation Analysis]
17 Xie Z, Li M, Hong H, Xu Q, He Z, Peng Z. Expression of N6-methyladenosine (m6A) regulators correlates with immune microenvironment characteristics and predicts prognosis in diffuse large cell lymphoma (DLBCL). Bioengineered 2021;12:6115-33. [PMID: 34482808 DOI: 10.1080/21655979.2021.1972644] [Reference Citation Analysis]
18 Bai Z, Zhao Y, Yang X, Wang L, Yin X, Chen Y, Lu J. A Novel Prognostic Ferroptosis-Related Long Noncoding RNA Signature in Clear Cell Renal Cell Carcinoma. J Oncol 2022;2022:6304824. [PMID: 35242188 DOI: 10.1155/2022/6304824] [Reference Citation Analysis]
19 Zhang L, Ke W, Hu P, Li Z, Geng W, Guo Y, Song B, Jiang H, Zhang X, Wan C. N6-Methyladenosine-Related lncRNAs Are Novel Prognostic Markers and Predict the Immune Landscape in Acute Myeloid Leukemia. Front Genet 2022;13:804614. [DOI: 10.3389/fgene.2022.804614] [Reference Citation Analysis]
20 Chen S, Zeng J, Huang L, Peng Y, Yan Z, Zhang A, Zhao X, Li J, Zhou Z, Wang S, Jing S, Hu M, Li Y, Wang D, Wang W, Yu H, Miao J, Li J, Deng Y, Li Y, Liu T, Xu D. RNA adenosine modifications related to prognosis and immune infiltration in osteosarcoma. J Transl Med 2022;20:228. [PMID: 35568866 DOI: 10.1186/s12967-022-03415-6] [Reference Citation Analysis]
21 Xu T, Gu H, Zhang C, Zhang W, Liang X, Cheng X. A Novel Risk Model Identified Based on Pyroptosis-Related lncRNA Predicts Overall Survival and Associates With the Immune Landscape of GC Patients. Front Genet 2022;13:843538. [DOI: 10.3389/fgene.2022.843538] [Reference Citation Analysis]
22 Zhang J, Shan B, Lin L, Dong J, Sun Q, Zhou Q, Chen J, Han X. Dissecting the Role of N6-Methylandenosine-Related Long Non-coding RNAs Signature in Prognosis and Immune Microenvironment of Breast Cancer. Front Cell Dev Biol 2021;9:711859. [PMID: 34692676 DOI: 10.3389/fcell.2021.711859] [Reference Citation Analysis]
23 Liang X, Zha L, Yu G, Guo X, Qin C, Cheng A, Wang Z, Laudadio I. Construction and Comprehensive Prognostic Analysis of a Novel Immune-Related lncRNA Signature and Immune Landscape in Gastric Cancer. International Journal of Genomics 2022;2022:1-23. [DOI: 10.1155/2022/4105280] [Reference Citation Analysis]
24 Ye L, Pan K, Fang S, Wu S, Chen S, Tang S, Wang N, Zhang H, Tong X, Shi X, Feng S, Xiang D, Zou R, Hu Y, Xue X, Guo G. Four Types of RNA Modification Writer-Related lncRNAs Are Effective Predictors of Prognosis and Immunotherapy Response in Serous Ovarian Carcinoma. Front Immunol 2022;13:863484. [DOI: 10.3389/fimmu.2022.863484] [Reference Citation Analysis]
25 Weng C, Wang L, Liu G, Guan M, Lu L. Identification of a N6-Methyladenosine (m6A)-Related lncRNA Signature for Predicting the Prognosis and Immune Landscape of Lung Squamous Cell Carcinoma. Front Oncol 2021;11:763027. [PMID: 34868980 DOI: 10.3389/fonc.2021.763027] [Reference Citation Analysis]
26 Zhang P, Liu G, Lu L. N6-Methylandenosine-Related lncRNA Signature Is a Novel Biomarkers of Prognosis and Immune Response in Colon Adenocarcinoma Patients. Front Cell Dev Biol 2021;9:703629. [PMID: 34336856 DOI: 10.3389/fcell.2021.703629] [Reference Citation Analysis]
27 Ma Y, Zhang H. Genomics and Prognosis Analysis of N6-Methyladenosine Regulators in Lung Adenocarcinoma. Front Genet 2021;12:746666. [PMID: 34956315 DOI: 10.3389/fgene.2021.746666] [Reference Citation Analysis]
28 Zhao Z, Liu H, Zhou X, Fang D, Ou X, Ye J, Peng J, Xu J. Necroptosis-Related lncRNAs: Predicting Prognosis and the Distinction between the Cold and Hot Tumors in Gastric Cancer. J Oncol 2021;2021:6718443. [PMID: 34790235 DOI: 10.1155/2021/6718443] [Reference Citation Analysis]
29 Yang X, Weng X, Yang Y, Jiang Z. Pyroptosis-Related lncRNAs Predict the Prognosis and Immune Response in Patients With Breast Cancer. Front Genet 2022;12:792106. [DOI: 10.3389/fgene.2021.792106] [Reference Citation Analysis]
30 Xu Y, Chen Y, Niu Z, Xing J, Yang Z, Yin X, Guo L, Zhang Q, Qiu H, Han Y. A Novel Pyroptotic and Inflammatory Gene Signature Predicts the Prognosis of Cutaneous Melanoma and the Effect of Anticancer Therapies. Front Med 2022;9:841568. [DOI: 10.3389/fmed.2022.841568] [Reference Citation Analysis]
31 Zhou W, Bai C, Long C, Hu L, Zheng Y. Construction and Characterization of Long Non-Coding RNA-Associated Networks to Reveal Potential Prognostic Biomarkers in Human Lung Adenocarcinoma. Front Oncol 2021;11:720400. [PMID: 34513699 DOI: 10.3389/fonc.2021.720400] [Reference Citation Analysis]
32 Yang LR, Lin ZY, Hao QG, Li TT, Zhu Y, Teng ZW, Zhang J. The prognosis biomarkers based on m6A-related lncRNAs for myeloid leukemia patients. Cancer Cell Int 2022;22:10. [PMID: 34996458 DOI: 10.1186/s12935-021-02428-3] [Reference Citation Analysis]